AstraZeneca Announced Voydeya Approved In Canada As Add-on Therapy To Ravulizumab Or Eculizumab For Adults With PNH Who Have Residual Hemolytic Anemia Due To Extravascular Hemolysis

Author: Benzinga Newsdesk | July 23, 2024 07:10am

Voydeya (danicopan tablets) has been approved in Canada as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH).1 Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant extravascular hemolysis (EVH) while treated with a C5 inhibitor.2,3

Posted In: AZN EWC